Journal Article

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

Cho, Deok-Kyu, Lee, Wang Soo, Yang, Jeong Hoon, Park, Hun Sik, Kim, Byung-Ok, Jeong, Jin-Ok, Cha, Kwang Soo, Kim, Sang-Hyun, Park, Hoon-Ki, Lee, Jong-Young, Bae, Jang-Ho, Oh, Ju-Hyeon, Park, Jong-Seon, Kang, Seung Ho, Song, Young Bin, Choi, Jin-Ho, Hwang, Jin-Yong, Choi, Rak Kyung, Kim, Jihoon, Choi, Seung-Hyuk, Gwon, Hyeon-Cheol, Kim, Doo-il, Hahn, Joo-Yong, Doh, Joon-Hyung, Suh, Il-Woo, Choi, Woong Gil, Kang, Won You, Choi, Ki Hong, Lim, Seong-Hoon, Ahn, Kyung-Ju, Lee, Jin Bae, Cho, Jang Hyun, Lee, Joo Myung, Chae, In-Ho, Kim, Moo Hyun, Chun, Woo Jung, Cho, Sang Cheol, Park, Yong Hawn, Jeong, Myung Ho, Choi, Jae Woong, Rha, Seung-Woon, Park, Taek Kyu, Hur, Seung-Ho, Jang, Woo Jin

2018

Overview

Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome. However, available data about the optimal duration of DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention are scant. We aimed to investigate whether a 6-month duration of DAPT would be non-inferior to the conventional 12-month or longer duration of DAPT in this population. We did a randomised, open-label, non-inferiority trial at 31 centres in South Korea. Patients were eligible if they had unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction, and underwent percutaneous coronary intervention. Enrolled patients were randomly assigned, via a web-based system by computer-generated block randomisation, to either the 6-month DAPT group or to the 12-month or longer DAPT group, with stratification by site, clinical presentation, and diabetes. Assessors were masked to treatment allocation. The primary endpoint was a composite of all-cause death, myocardial infarction, or stroke at 18 months after the index procedure in the intention-to-treat population. Secondary endpoints were the individual components of the primary endpoint; definite or probable stent thrombosis as defined by the Academic Research Consortium; and Bleeding Academic Research Consortium (BARC) type 2–5 bleeding at 18 months after the index procedure. The primary endpoint was also analysed per protocol. This trial is registered with ClinicalTrials.gov, number NCT01701453. Between Sept 5, 2012, and Dec 31, 2015, we randomly assigned 2712 patients; 1357 to the 6-month DAPT group and 1355 to the 12-month or longer DAPT group. Clopidogrel was used as a P2Y12 inhibitor for DAPT in 1082 (79·7%) patients in the 6-month DAPT group and in 1109 (81·8%) patients in the 12-month or longer DAPT group. The primary endpoint occurred in 63 patients in the 6-month DAPT group and in 56 patients in the 12-month or longer DAPT group (cumulative event rate 4·7% vs 4·2%; absolute risk difference 0·5%; upper limit of one-sided 95% CI 1·8%; pnon-inferiority=0·03 with a predefined non-inferiority margin of 2·0%). Although all-cause mortality did not differ significantly between the 6-month DAPT group and the 12-month or longer DAPT group (35 [2·6%] patients vs 39 [2·9%]; hazard ratio [HR] 0·90 [95% CI 0·57–1·42]; p=0·90) and neither did stroke (11 [0·8%] patients vs 12 [0·9%]; 0·92 [0·41–2·08]; p=0·84), myocardial infarction occurred more frequently in the 6-month DAPT group than in the 12-month or longer DAPT group (24 [1·8%] patients vs ten [0·8%]; 2·41 [1·15–5·05]; p=0·02). 15 (1·1%) patients had stent thrombosis in the 6-month DAPT group compared with ten (0·7%) in the 12-month or longer DAPT group (HR 1·50 [95% CI 0·68–3·35]; p=0·32). The rate of BARC type 2–5 bleeding was 2·7% (35 patients) in the 6-month DAPT group and 3·9% (51 patients) in the 12-month or longer DAPT group (HR 0·69 [95% CI 0·45–1·05]; p=0·09). Results from the per-protocol analysis were similar to those from the intention-to-treat analysis. The increased risk of myocardial infarction with 6-month DAPT and the wide non-inferiority margin prevent us from concluding that short-term DAPT is safe in patients with acute coronary syndrome undergoing percutaneous coronary intervention with current-generation DES. Prolonged DAPT in patients with acute coronary syndrome without excessive risk of bleeding should remain the standard of care. Abbott Vascular Korea, Medtronic Vascular Korea, Biosensors Inc, and Dong-A ST.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Acute coronary syndromes / Angina / Angioplasty / Antiplatelet therapy / Aspirin / Biosensors / Bleeding / Cardiology / Cardiovascular disease / Cerebral infarction / Clinical trials / Clopidogrel / Consortia / Diabetes mellitus / Drug delivery / Evidence-based medicine / Heart attacks / Implantation / Implants / Inhibitors / Motivation / Myocardial infarction / Patients / Randomization / Review boards / Risk analysis / Stents / Stroke / Surgical implants / Therapy / Thromboembolism / Thrombosis